Lineage Cell Therapeutics News

Lineage Cell Therapeutics Q1 2024 Earnings: Aligns With EPS Projections Amidst Revenue Declines

Yahoo FinanceMay 11 03:49

Earnings Call Summary | Lineage Cell Therapeutics(LCTX.US) Q1 2024 Earnings Conference

The following is a summary of the Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript:Financial Performance:Lineage Cell Therapeutics reported Q1 2024 cash, cash equivalents and ma

Futu NewsMay 10 20:59 · Conference Call

Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.03) per share from th

BenzingaMay 10 05:03

Lineage Cell Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 05:03 · Announcements

Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, Vs. Street Est of $1.36M

04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M

MT NewswiresMay 10 04:03

Lineage Cell Therapeutics 1Q Loss/Shr 4c >LCTX

Lineage Cell Therapeutics 1Q Loss/Shr 4c >LCTX

Dow JonesMay 10 04:03

Press Release: Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update -- Established New Services Agreement with Genentech to Support Ongoing Development of th

Dow JonesMay 10 04:01

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

PDF Version Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported

Lineage Cell TherapeuticsMay 10 04:01

Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patients

TipRanksMay 8 12:35

Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular...

Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geog

BenzingaMay 7 02:13

HC Wainwright & Co. : The Lineage Cell Therapeutics (LCTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.

HC Wainwright & Co. : The Lineage Cell Therapeutics (LCTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.

Zhitong FinanceMay 6 22:41

OpRegen (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or increases in

BusinesswireMay 6 20:00

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell the

BusinesswireMay 2 20:00

Lineage Cell Therapeutics Board Chairman Passes Away

Seeking AlphaApr 30 04:39

Lineage Cell Therapeutics: Saddened to Report the Passing of Long-Serving Chmn of the Bd of Directors, Alfred Kingsley >LCTX

Lineage Cell Therapeutics: Saddened to Report the Passing of Long-Serving Chmn of the Bd of Directors, Alfred Kingsley >LCTX

Dow JonesApr 30 04:33

Lineage Announces Changes to Board of Directors

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr.

BusinesswireApr 30 04:30

Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley

Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley

BenzingaMar 23 04:36

Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release

TipRanksMar 19 13:46

15 Best Anti-Aging Foods for Youthful Skin

Yahoo FinanceMar 18 22:31

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Business WireMar 18 20:00